Actinium Pharmaceuticals (ATNM) Net Income (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Net Income of -$5.7 million for Q1 2026, up 64.43% year-over-year from -$3.5 million in Q1 2025, and up 6.38% quarter-over-quarter from -$6.1 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Net Income (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Net Income for 17 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 64.43% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$25.1 million (up 55.51% YoY), while the FY2025 annual figure was -$33.3 million, up 12.95% from the prior year.
- Net Income climbed to -$5.7 million in Q1 2026 per ATNM's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Net Income topped out at -$5.3 million in Q1 2022 and bottomed at -$21.8 million in Q2 2024.
- Historically, Net Income has averaged -$11.4 million across 5 years, with a median of -$11.3 million in 2022.
- Annual changes were most pronounced in 2023 — Net Income sank 123.16% — and 2025, when it jumped 68.16%.
- Actinium Pharmaceuticals' Net Income stood at -$11.3 million in 2022, then rose by 16.44% to -$9.5 million in 2023, then climbed by 28.16% to -$6.8 million in 2024, then rose by 10.19% to -$6.1 million in 2025, then climbed by 6.38% to -$5.7 million in 2026.
- Business Quant data shows ATNM's Net Income at -$5.7 million in Q1 2026, -$6.1 million in Q4 2025, and -$6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.90 Mn |
| Mar 31, 2026 | -5.72 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -6.31 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Mar 31, 2025 | -16.09 Mn |
| Dec 31, 2024 | -6.81 Mn |
| Sep 30, 2024 | -11.69 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -21.22 Mn |
| Dec 31, 2023 | -9.48 Mn |
| Sep 30, 2023 | -15.02 Mn |
| Jun 30, 2023 | -15.18 Mn |
| Mar 31, 2023 | -11.73 Mn |
| Dec 31, 2022 | -11.34 Mn |
| Sep 30, 2022 | -15.18 Mn |
| Jun 30, 2022 | -7.87 Mn |
| Mar 31, 2022 | -5.26 Mn |
| Dec 31, 2021 | -8.14 Mn |
| Sep 30, 2021 | -8.68 Mn |